SEC Form 4 · accession 0001209191-18-063384
ANAPTYSBIO, INC · ANAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marco Londei
Officer — Chief Medical Officer
Period of report
Dec 17, 2018
Accepted (ET)
Dec 18, 2018 · 9:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001370053
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 17, 2018 | M | 8,048 | $0.70 | A | 152,925 | D | |
| Common Stock | Dec 17, 2018 | M | 22,000 | $6.93 | A | 174,925 | D | |
| Common StockF2 | Dec 17, 2018 | S | 12,120 | $65.3612 | D | 162,805 | D | |
| Common StockF3 | Dec 17, 2018 | S | 3,185 | $66.3787 | D | 159,620 | D | |
| Common StockF4 | Dec 17, 2018 | S | 8,002 | $67.5686 | D | 151,618 | D | |
| Common StockF5 | Dec 17, 2018 | S | 6,741 | $68.4732 | D | 144,877 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F6 | $0.70 | Dec 17, 2018 | M | 8,048 | D | — | Oct 27, 2024 | Common Stock | 8,048 | 10,060 | D |
| Employee Stock Option (Right to Buy)F8,F7 | $6.93 | Dec 17, 2018 | M | 22,000 | D | — | Aug 13, 2025 | Common Stock | 22,000 | 70,223 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.92 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.02 to $68.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.05 to $68.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F7The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F8In addition to the remaining options to purchase 80,283 shares of common stock as set forth in Table II, the Reporting Person also holds (i) 144,877 shares of common stock held directly; and (ii) additional options to purchase up to an aggregate of 138,000 shares of common stock, which options vest according to their terms.